

**Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis And DMPK Studies, Toxicology Testing, Chemistry, Manufacturing, and Controls (CMC), Drug Safety and Efficacy Testing, Others), By Model Type (Patient-Derived Organoid (PDO) Models, Patient-Derived Xenograft (PDX) Models), By End User (Pharmaceutical Companies, Academic and Research Institutes, Medical Device Companies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032**

Market Report | 2023-10-09 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

Preclinical CRO Market Analysis and Insights

The Preclinical CRO Market size is anticipated to reach USD 5.82 Billion in 2023 and it is projected to reach USD 10.97 Billion by 2032, growing at a CAGR of % during the forecast period.

The Global Preclinical CRO Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Preclinical CRO Market growth, Size report provides a comprehensive analysis of the Medical Devices industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Preclinical CRO Market includes major suppliers & Independent Consultants among others.

#### Global Market Scope and Preclinical CRO Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Preclinical CRO Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

#### Preclinical CRO Market Country Level Analysis

The Global Preclinical CRO Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Preclinical CRO Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

#### Top Players in Preclinical CRO Market

Some of the other major highlights of the demand for Preclinical CRO Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Preclinical CRO Market during the forecast period.

Charles River Laboratories International, Inc.

Covance Inc.

ICON plc

Medpace, Inc.

WuXi AppTec

Envigo

PRA Health Sciences

Syngene International Limited

Eurofins Scientific

Parexel International Corporation

SGS SA

MPI Research

Crown Bioscience, Inc.

Toxikon Corporation

Pharmaron

#### Market Segmentation

The Global Preclinical CRO Market Share, Demand provides the most up-to-date Medical Devices industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

#### By Service

Bioanalysis And DMPK Studies

Toxicology Testing

Chemistry, Manufacturing, and Controls (CMC)

Drug Safety and Efficacy Testing

Others

#### By Model Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Patient-Derived Organoid (PDO) Models  
Patient-Derived Xenograft (PDX) Models

By End User

Pharmaceutical Companies  
Academic and Research Institutes  
Medical Device Companies  
Others

Regions Coverd

North America

U.S.  
Canada

Europe

U.K.  
Germany  
France  
Spain  
Italy  
Russia  
Nordic  
Benelux  
Rest of Europe

APAC

China  
Korea  
Japan  
India  
Australia  
Singapore  
Taiwan  
South East Asia  
Rest of Asia-Pacific

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Middle East and Africa

UAE  
Turkey  
Saudi Arabia  
South Africa  
Egypt  
Nigeria  
Rest of MEA

## LATAM

Brazil  
Mexico  
Argentina  
Chile  
Colombia  
Rest of LATAM

### Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

### **Table of Contents:**

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies
  - 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors
  - 4.3 Latest Macro Economic Indicators
  - 4.4 Geopolitical Impact
  - 4.5 Technology Factors
- 5 Market Assessment

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1 Porters Five Forces Analysis
- 5.2 Value Chain Analysis
- 6 Global Preclinical CRO Market Size Analysis
  - 6.1 By Service
    - 6.1.1 Bioanalysis and DMPK studies
      - 6.1.1.1 In vitro ADME
      - 6.1.1.2 In-vivo PK
    - 6.1.2 Toxicology Testing
      - 6.1.2.1 GLP
      - 6.1.2.2 Non-GLP
    - 6.1.3 Compound Management
      - 6.1.3.1 Process R&D
      - 6.1.3.2 Custom Synthesis
      - 6.1.3.3 Others
    - 6.1.4 Chemistry
      - 6.1.4.1 Medicinal Chemistry
      - 6.1.4.2 Computation Chemistry
    - 6.1.5 Safety Pharmacology
    - 6.1.6 Others
  - 6.2 By Model
    - 6.2.1 Patient-Derived Organoid (PDO) Model
    - 6.2.2 Patient-Derived Xenograft Model
  - 6.3 By Applications
    - 6.3.1 Oncology
    - 6.3.2 Neurology
    - 6.3.3 Cardiology
    - 6.3.4 Infectious Diseases
    - 6.3.5 Metabolic Disorders
    - 6.3.6 Others
  - 6.4 By End-User
    - 6.4.1 Pharmaceutical and Biotechnological Companies
    - 6.4.2 Government and Academic Institutes
    - 6.4.3 Medical Device Companies
    - 6.4.4 Others
- 7 North America Market Analysis
  - 7.1 By Service
    - 7.1.1 Bioanalysis and DMPK studies
      - 7.1.1.1 In vitro ADME
      - 7.1.1.2 In-vivo PK
    - 7.1.2 Toxicology Testing
      - 7.1.2.1 GLP
      - 7.1.2.2 Non-GLP
    - 7.1.3 Compound Management
      - 7.1.3.1 Process R&D
      - 7.1.3.2 Custom Synthesis
      - 7.1.3.3 Others
    - 7.1.4 Chemistry

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.1.4.1 Medicinal Chemistry
- 7.1.4.2 Computation Chemistry
- 7.1.5 Safety Pharmacology
- 7.1.6 Others
- 7.2 By Model
  - 7.2.1 Patient-Derived Organoid (PDO) Model
  - 7.2.2 Patient-Derived Xenograft Model
- 7.3 By Applications
  - 7.3.1 Oncology
  - 7.3.2 Neurology
  - 7.3.3 Cardiology
  - 7.3.4 Infectious Diseases
  - 7.3.5 Metabolic Disorders
  - 7.3.6 Others
- 7.4 By End-User
  - 7.4.1 Pharmaceutical and Biotechnological Companies
  - 7.4.2 Government and Academic Institutes
  - 7.4.3 Medical Device Companies
  - 7.4.4 Others
- 7.4 U.S.
- 7.5 Canada
- 8 Europe Market Analysis
  - 8.1 By Service
    - 8.1.1 Bioanalysis and DMPK studies
      - 8.1.1.1 In vitro ADME
      - 8.1.1.2 In-vivo PK
    - 8.1.2 Toxicology Testing
      - 8.1.2.1 GLP
      - 8.1.2.2 Non-GLP
    - 8.1.3 Compound Management
      - 8.1.3.1 Process R&D
      - 8.1.3.2 Custom Synthesis
      - 8.1.3.3 Others
    - 8.1.4 Chemistry
      - 8.1.4.1 Medicinal Chemistry
      - 8.1.4.2 Computation Chemistry
    - 8.1.5 Safety Pharmacology
    - 8.1.6 Others
  - 8.2 By Model
    - 8.2.1 Patient-Derived Organoid (PDO) Model
    - 8.2.2 Patient-Derived Xenograft Model
  - 8.3 By Applications
    - 8.3.1 Oncology
    - 8.3.2 Neurology
    - 8.3.3 Cardiology
    - 8.3.4 Infectious Diseases
    - 8.3.5 Metabolic Disorders

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.3.6 Others
- 8.4 By End-User
  - 8.4.1 Pharmaceutical and Biotechnological Companies
  - 8.4.2 Government and Academic Institutes
  - 8.4.3 Medical Device Companies
  - 8.4.4 Others
- 8.4 U.K.
- 8.5 Germany
- 8.6 France
- 8.7 Spain
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic
- 8.11 Benelux
- 8.12 Rest of Europe
- 9 APAC Market Analysis
  - 9.1 By Service
    - 9.1.1 Bioanalysis and DMPK studies
      - 9.1.1.1 In vitro ADME
      - 9.1.1.2 In-vivo PK
    - 9.1.2 Toxicology Testing
      - 9.1.2.1 GLP
      - 9.1.2.2 Non-GLP
    - 9.1.3 Compound Management
      - 9.1.3.1 Process R&D
      - 9.1.3.2 Custom Synthesis
      - 9.1.3.3 Others
    - 9.1.4 Chemistry
      - 9.1.4.1 Medicinal Chemistry
      - 9.1.4.2 Computation Chemistry
    - 9.1.5 Safety Pharmacology
    - 9.1.6 Others
  - 9.2 By Model
    - 9.2.1 Patient-Derived Organoid (PDO) Model
    - 9.2.2 Patient-Derived Xenograft Model
  - 9.3 By Applications
    - 9.3.1 Oncology
    - 9.3.2 Neurology
    - 9.3.3 Cardiology
    - 9.3.4 Infectious Diseases
    - 9.3.5 Metabolic Disorders
    - 9.3.6 Others
  - 9.4 By End-User
    - 9.4.1 Pharmaceutical and Biotechnological Companies
    - 9.4.2 Government and Academic Institutes
    - 9.4.3 Medical Device Companies
    - 9.4.4 Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4 China
- 9.5 Korea
- 9.6 Japan
- 9.7 India
- 9.8 Australia
- 9.9 Singapore
- 9.10 Taiwan
- 9.11 South East Asia
- 9.12 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
- 10.1 By Service
  - 10.1.1 Bioanalysis and DMPK studies
    - 10.1.1.1 In vitro ADME
    - 10.1.1.2 In-vivo PK
  - 10.1.2 Toxicology Testing
    - 10.1.2.1 GLP
    - 10.1.2.2 Non-GLP
  - 10.1.3 Compound Management
    - 10.1.3.1 Process R&D
    - 10.1.3.2 Custom Synthesis
    - 10.1.3.3 Others
  - 10.1.4 Chemistry
    - 10.1.4.1 Medicinal Chemistry
    - 10.1.4.2 Computation Chemistry
  - 10.1.5 Safety Pharmacology
  - 10.1.6 Others
- 10.2 By Model
  - 10.2.1 Patient-Derived Organoid (PDO) Model
  - 10.2.2 Patient-Derived Xenograft Model
- 10.3 By Applications
  - 10.3.1 Oncology
  - 10.3.2 Neurology
  - 10.3.3 Cardiology
  - 10.3.4 Infectious Diseases
  - 10.3.5 Metabolic Disorders
  - 10.3.6 Others
- 10.4 By End-User
  - 10.4.1 Pharmaceutical and Biotechnological Companies
  - 10.4.2 Government and Academic Institutes
  - 10.4.3 Medical Device Companies
  - 10.4.4 Others
- 10.4 UAE
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 South Africa
- 10.8 Egypt
- 10.9 Nigeria

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.10 Rest of MEA
- 11 LATAM Market Analysis
  - 11.1 By Service
    - 11.1.1 Bioanalysis and DMPK studies
      - 11.1.1.1 In vitro ADME
      - 11.1.1.2 In-vivo PK
    - 11.1.2 Toxicology Testing
      - 11.1.2.1 GLP
      - 11.1.2.2 Non-GLP
    - 11.1.3 Compound Management
      - 11.1.3.1 Process R&D
      - 11.1.3.2 Custom Synthesis
      - 11.1.3.3 Others
    - 11.1.4 Chemistry
      - 11.1.4.1 Medicinal Chemistry
      - 11.1.4.2 Computation Chemistry
    - 11.1.5 Safety Pharmacology
    - 11.1.6 Others
  - 11.2 By Model
    - 11.2.1 Patient-Derived Organoid (PDO) Model
    - 11.2.2 Patient-Derived Xenograft Model
  - 11.3 By Applications
    - 11.3.1 Oncology
    - 11.3.2 Neurology
    - 11.3.3 Cardiology
    - 11.3.4 Infectious Diseases
    - 11.3.5 Metabolic Disorders
    - 11.3.6 Others
  - 11.4 By End-User
    - 11.4.1 Pharmaceutical and Biotechnological Companies
    - 11.4.2 Government and Academic Institutes
    - 11.4.3 Medical Device Companies
    - 11.4.4 Others
  - 11.4 Brazil
  - 11.5 Mexico
  - 11.6 Argentina
  - 11.7 Chile
  - 11.8 Colombia
  - 11.9 Rest of LATAM
- 12 Competitive Landscape
  - 12.1 Global Preclinical CRO Market Share By Players
  - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
  - 13.1 American International Industries (GIGI)
    - 13.1.1 Overview
    - 13.1.2 Business Information
    - 13.1.3 Revenue

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.1.4 ASP
- 13.1.5 Swot Analysis
- 13.1.6 Recent Developments
- 13.2 Covance Inc.
- 13.3 ICON plc
- 13.4 Medpace, Inc.
- 13.5 WuXi AppTec
- 13.6 Envigo
- 13.7 PRA Health Sciences
- 13.8 Syngene International Limited
- 13.9 Eurofins Scientific
- 13.10 Parexel International Corporation
- 13.11 SGS SA
- 13.12 MPI Research
- 13.13 Crown Bioscience, Inc.
- 13.14 Toxikon Corporation
- 13.15 Pharmaron
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
    - 14.1.3 Secondary And Primary Research
      - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis And DMPK Studies, Toxicology Testing, Chemistry, Manufacturing, and Controls (CMC), Drug Safety and Efficacy Testing, Others), By Model Type (Patient-Derived Organoid (PDO) Models, Patient-Derived Xenograft (PDX) Models), By End User (Pharmaceutical Companies, Academic and Research Institutes, Medical Device Companies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032**

Market Report | 2023-10-09 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Job title\*

Company Name\*

Address\*

Zip Code\*

EU Vat / Tax ID / NIP number\*

City\*

Country\*

Date

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com